Frank Shafer Selected Research

sutimlimab

1/2022	Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
1/2022	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
1/2022	Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank Shafer Research Topics

Disease

3	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2022 - 01/2022
2	Hemorrhage 12/2015 - 10/2013
2	Hemophilia A (Haemophilia) 05/2015 - 10/2013
1	Rhinitis 01/2022
1	Headache (Headaches) 01/2022
1	Hemolysis 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Raynaud Disease (Raynaud's Disease) 01/2022
1	Fatigue 01/2022
1	Hemophilia B (Haemophilia B) 12/2015
1	Inflammation (Inflammations) 10/2013
1	Body Weight (Weight, Body) 10/2013
1	Joint Diseases (Joint Disease) 10/2013

Drug/Important Bio-Agent (IBA)

3	sutimlimabIBA 01/2022 - 01/2022
2	Factor IX (Coagulation Factor IX)FDA LinkGeneric 12/2015 - 10/2013
1	Monoclonal AntibodiesIBA 01/2022
1	Complement C1s (C1 Esterase)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	recombinant factor VIII SQIBA 05/2015
1	Factor VIII (Coagulation Factor VIII)IBA 10/2013
1	Hemostatics (Antihemorrhagics)IBA 10/2013